{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:13:43Z","timestamp":1791148423498,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T00:00:00Z","timestamp":1263340800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mycopathologia"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1007\/s11046-009-9271-z","type":"journal-article","created":{"date-parts":[[2010,1,12]],"date-time":"2010-01-12T21:53:33Z","timestamp":1263333213000},"page":"333-341","source":"Crossref","is-referenced-by-count":17,"title":["Nystatin-Intralipid Preparation: Characterization and In Vitro Activity Against Yeasts and Molds"],"prefix":"10.1007","volume":"169","author":[{"given":"R.","family":"Semis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Polacheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,1,13]]},"reference":[{"key":"9271_CR1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/13693780701218689","volume":"45","author":"J Perlroth","year":"2007","unstructured":"Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol. 2007;45:321\u201346.","journal-title":"Med Mycol"},{"key":"9271_CR2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","volume":"39","author":"H Wisplinghoff","year":"2004","unstructured":"Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309\u201317.","journal-title":"Clin Infect Dis"},{"key":"9271_CR3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1513\/pats.200510-110JH","volume":"3","author":"CA Kauffman","year":"2006","unstructured":"Kauffman CA. Fungal infections. Proc Am Thorac Soc. 2006;3:35\u201340.","journal-title":"Proc Am Thorac Soc"},{"key":"9271_CR4","unstructured":"Richardson MD, Warnock DW. Antifungal drugs. In: Fungal infection. Diagnosis and management. Blackwell; 2000. p. 29\u201379."},{"key":"9271_CR5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.det.2007.01.002","volume":"25","author":"AY Zhang","year":"2007","unstructured":"Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. Dermatol Clin. 2007;25:165\u201383.","journal-title":"Dermatol Clin"},{"issue":"Suppl 1","key":"9271_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2006.03.013","volume":"27","author":"M Kleinberg","year":"2006","unstructured":"Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006;27(Suppl 1):12\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"9271_CR7","first-page":"67","volume":"6","author":"AW Ng","year":"2003","unstructured":"Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharmaceut Sci. 2003;6:67\u201383.","journal-title":"J Pharm Pharmaceut Sci"},{"key":"9271_CR8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/jac\/39.5.655","volume":"39","author":"Y Shadkhan","year":"1997","unstructured":"Shadkhan Y, Segal E, Bor A, Gov Y, Rubin M, Lichtenberg D. The use of commercially available lipid emulsions for the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother. 1997;39:655\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"9271_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13693780310001598871","volume":"42","author":"E Sionov","year":"2004","unstructured":"Sionov E, Segal E. Treatment of murine systemic aspergillosis with polyene-intralipid admixtures. Med Mycol. 2004;42:73\u201380.","journal-title":"Med Mycol"},{"key":"9271_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0928-8244(03)00230-X","volume":"39","author":"E Sionov","year":"2003","unstructured":"Sionov E, Segal E. Polyene and cytokine treatment of experimental aspergillosis. FEMS Immunol Med Microbiol. 2003;39:221\u20137.","journal-title":"FEMS Immunol Med Microbiol"},{"key":"9271_CR11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/jac\/44.6.787","volume":"44","author":"Y Shadkchan","year":"1999","unstructured":"Shadkchan Y, Segal E. Antifungal activity of amphotericin B-lipid admixtures in experimental systemic candidosis in naive mice. J Antimicrob Chemother. 1999;44:787\u201390.","journal-title":"J Antimicrob Chemother"},{"key":"9271_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jac\/48.2.245","volume":"48","author":"Y Shadkchan","year":"2001","unstructured":"Shadkchan Y, Segal E. Treatment of experimental candidosis with amphotericin B-Intralipid admixtures in immunocompromised mice. J Antimicrob Chemother. 2001;48:245\u201351.","journal-title":"J Antimicrob Chemother"},{"key":"9271_CR13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/714043894","volume":"41","author":"Y Shadkchan","year":"2003","unstructured":"Shadkchan Y, Zaslavsky Z, Segal E. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid. Med Mycol. 2003;41:15\u20139.","journal-title":"Med Mycol"},{"key":"9271_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13693780310001624583","volume":"42","author":"Y Shadkchan","year":"2004","unstructured":"Shadkchan Y, Keisari Y, Segal E. Cytokines in mice treated with amphotericin B-intralipid. Med Mycol. 2004;42:123\u20138.","journal-title":"Med Mycol"},{"key":"9271_CR15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/jac\/30.4.535","volume":"30","author":"P Moreau","year":"1992","unstructured":"Moreau P, Milpied N, Fayette N, Ram\u00e9e JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992;30:535\u201341.","journal-title":"J Antimicrob Chemother"},{"key":"9271_CR16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jac\/31.5.806","volume":"31","author":"C Washington","year":"1993","unstructured":"Washington C, Lance M, Davis SS. Toxicity of amphotericin B emulsion formulations. J Antimicrob Chemother. 1993;31:806\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"9271_CR17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1469-0691.1997.tb00282.x","volume":"3","author":"P Chavanet","year":"1997","unstructured":"Chavanet P, Clement C, Duong M, Buisson M, D\u2019Athis P, Dumas M, et al. Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate\u2014fat emulsion in HIV-infected patients with oral candidosis. Clin Microbiol Infect. 1997;3:455\u201361.","journal-title":"Clin Microbiol Infect"},{"key":"9271_CR18","unstructured":"National Committee for Clinical Laboratory Standarts. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Wayne, PA, USA, 1997."},{"key":"9271_CR19","unstructured":"National Committee for Clinical Laboratory Standarts. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. NCCLS, Wayne, PA, USA, 1997."},{"key":"9271_CR20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jac\/32.1.123","volume":"32","author":"LC Souza","year":"1993","unstructured":"Souza LC, Maranhao RC, Schreier S, Campa A. In vitro and in vivo studies of the decrease of amphotericin B toxicity upon association with a triglyceride-rich emulsion. J Antimicrob Chemother. 1993;32:123\u201332.","journal-title":"J Antimicrob Chemother"},{"key":"9271_CR21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2141.2005.05763.x","volume":"131","author":"C Lass-Fl\u00f6rl","year":"2005","unstructured":"Lass-Fl\u00f6rl C, Griff K, Mayr A, Petzer A, Gastl G, Bonatti H, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol. 2005;131:201\u20137.","journal-title":"Br J Haematol"},{"key":"9271_CR22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/cncr.20554","volume":"101","author":"RY Hachem","year":"2004","unstructured":"Hachem RY, Kontoyiannis DP, Boktour MR, Afif C, Cooksley C, Bodey GP, et al. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer. 2004;101:1594\u2013600.","journal-title":"Cancer"},{"key":"9271_CR23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1399-302X.2005.00236.x","volume":"20","author":"T Kuriyama","year":"2005","unstructured":"Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol. 2005;20:349\u201353.","journal-title":"Oral Microbiol Immunol"},{"key":"9271_CR24","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1128\/JCM.40.4.1406-1412.2002","volume":"40","author":"S Arikan","year":"2002","unstructured":"Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, Paetznick V, Gordon D, Wallace T, et al. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol. 2002;40:1406\u201312.","journal-title":"J Clin Microbiol"},{"key":"9271_CR25","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/AAC.43.5.1264","volume":"43","author":"KL Oakley","year":"1999","unstructured":"Oakley KL, Moore CB, Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother. 1999;43:1264\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"9271_CR26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1128\/AAC.42.6.1412","volume":"42","author":"EM Johnson","year":"1998","unstructured":"Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998;42:1412\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"9271_CR27","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JCM.37.7.2343-2345.1999","volume":"37","author":"DA Sutton","year":"1999","unstructured":"Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol. 1999;37:2343\u20135.","journal-title":"J Clin Microbiol"},{"key":"9271_CR28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2460\/javma.231.7.1086","volume":"231","author":"EC Ledbetter","year":"2007","unstructured":"Ledbetter EC, Patten VH, Scarlett JM, Vermeylen FM. In vitro susceptibility patterns of fungi associated with keratomycosis in horses of the northeastern United States: 68 cases (1987\u20132006). J Am Vet Med Assoc. 2007;231:1086\u201391.","journal-title":"J Am Vet Med Assoc"},{"key":"9271_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1081\/PFC-100103573","volume":"36","author":"MN Tzatzarakis","year":"2001","unstructured":"Tzatzarakis MN, Tsatsakis AM, Charvalos E, Vakalounakis D. Comparison of in vitro activities, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. J Environ Sci Health. 2001;36:331\u201340.","journal-title":"J Environ Sci Health"}],"container-title":["Mycopathologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-009-9271-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11046-009-9271-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11046-009-9271-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T17:52:14Z","timestamp":1590515534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11046-009-9271-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,13]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["9271"],"URL":"https:\/\/doi.org\/10.1007\/s11046-009-9271-z","relation":{},"ISSN":["0301-486X","1573-0832"],"issn-type":[{"value":"0301-486X","type":"print"},{"value":"1573-0832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,13]]}}}